Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2019; 10(5): 280-290
Published online May 15, 2019. doi: 10.4239/wjd.v10.i5.280
Published online May 15, 2019. doi: 10.4239/wjd.v10.i5.280
Management of diabetic dyslipidemia: An update
Ishwarlal Jialal, California North-state University College of Medicine, VA Medical Center, Mather, CA 95757, United States
Gurdeep Singh, Lady of Lourdes Memorial Hospital, New York, NY 10041, United States
Author contributions: Jialal I and Singh G both contributed substantially to the work. Jialal I devised the format and edited to final submission. Singh G worked on the drafts and contributed significantly to the writing and referencing.
Conflict-of-interest statement: None of the authors have any conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ishwarlal Jialal, MD, PhD, Professor, Assistant Dean, California North-state University College of Medicine, VA Medical Center, 9700 West Taron Drive, Elk Grove, Mather, CA 95757, United States. ishwarlal.jialal@cnsu.edu
Telephone: +1-530-7502859 Fax: +1-916-6867310
Received: March 11, 2019
Peer-review started: March 12, 2019
First decision: May 8, 2019
Revised: May 13, 2019
Accepted: May 13, 2019
Article in press: May 14, 2019
Published online: May 15, 2019
Peer-review started: March 12, 2019
First decision: May 8, 2019
Revised: May 13, 2019
Accepted: May 13, 2019
Article in press: May 14, 2019
Published online: May 15, 2019
Core Tip
Core tip: Atherosclerotic cardiovascular disease (ASCVD) is the major cause of mortality in diabetes. Low-density lipoprotein (LDL)-cholesterol lowering with statins reduce ASCVD and is the mainstay of therapy. Also, both ezetimibe and PCSK9 inhibitors are useful strategies when statins cannot be tolerated or the LDL-cholesterol goal is not achieved.